IL6 and interstitial lung disease: This amplified secretion of IL-6 can also induce STAT3-mediated fibroblast-to-mesenchymal transition (FMT) [31], resulting in de-differentiation of fibroblasts into myofibroblasts with a mesenchymal phenotype, contributing to the development of ILD [32].